1-4 of 4
John M. Kaczmar
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract B022: Immediate post-treatment detection of minimal residual disease in HPV-Driven oropharyngeal cancer is associated with high risk of recurrence

Scott A Roof, James Jabalee, Eleni M Rettig, Rocco Ferrandino, Sida Chen, Marshall R Posner, Krzysztof J Misiukiewicz, Eric M Gender, Raymond L Chai, John Sims, Elaine Thrash, Scott J Stern, Noah S Kalman, Sreenija Yarlagadda, Adam Raben, Lydia Clements, Abie Mendelsohn, John M Kaczmar, Yadav Pandey, Mihir Bhayani, Catherine DV Fitz, Glenn J Hanna
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (21_Supplement): B022.
https://doi.org/10.1158/1557-3265.LIQBIOP24-B022
Published: 13 November 2024
View article titled, Abstract B022: Immediate post-treatment detection of minimal residual disease in HPV-Driven oropharyngeal cancer is associated with high risk of recurrence
Journal Articles

Negative Predictive Value of Circulating Tumor Tissue Modified Viral (TTMV)-HPV DNA for HPV-driven Oropharyngeal Cancer Surveillance

Glenn J. Hanna, Scott A. Roof, Jamie Jabalee, Eleni M. Rettig, Rocco Ferrandino, II, Sida Chen, Marshall R. Posner, Krzysztof J. Misiukiewicz, Eric M. Genden, Raymond L. Chai, John Sims, Elaine Thrash, Scott J. Stern, Noah S. Kalman, Sreenija Yarlagadda, Adam Raben, Lydia Clements, Abie Mendelsohn, John M. Kaczmar, Yadav Pandey, Mihir Bhayani, Piyush Gupta, Charlotte Kuperwasser, Catherine Del Vecchio Fitz, Barry M. Berger
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (20): 4306–4313.
https://doi.org/10.1158/1078-0432.CCR-23-1478
Published: 13 October 2023
View article titled, Negative Predictive Value of Circulating Tumor Tissue Modified Viral (TTMV)-HPV DNA for HPV-driven Oropharyngeal Cancer Surveillance
Open the PDF for Negative Predictive Value of Circulating Tumor Tissue Modified Viral (TTMV)-HPV DNA for HPV-driven Oropharyngeal Cancer Surveillance in another window
Includes: Supplementary data
Journal Articles

Abstract PO-045: Utility of circulating tumor tissue modified viral (TTMV)-HPV DNA to resolve clinically indeterminate findings in patients following definitive treatment for HPV-driven oropharyngeal cancer

Scott Roof, Glenn Hanna, James Jabalee, Eleni Rettig, Rocco Ferrandino, Sida Chen, Marshall R. Posner, Krzysztof J. Misiukiewicz, Eric M. Genden, Raymond L. Chai, John Sims, Elaine Thrash, Scott Stern, Noah S. Kalman, Sreenija Yarlagadda, Adam Raben, Lydia Clements, Abie Mendelsohn, John M. Kaczmar, Yadav Pandey, Mihir Bhayani, Piyush Gupta, Charlotte Kuperwasser, Catherine Del Vecchio Fitz, Barry M. Berger
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (18_Supplement): PO-045.
https://doi.org/10.1158/1557-3265.AACRAHNS23-PO-045
Published: 15 September 2023
View article titled, Abstract PO-045: Utility of circulating tumor tissue modified viral (TTMV)-HPV DNA to resolve clinically indeterminate findings in patients following definitive treatment for HPV-driven oropharyngeal cancer
Journal Articles

Phase II Clinical Trial of Neoadjuvant and Adjuvant Pembrolizumab in Resectable Local–Regionally Advanced Head and Neck Squamous Cell Carcinoma

Trisha M. Wise-Draper, Shuchi Gulati, Sarah Palackdharry, Benjamin H. Hinrichs, Francis P. Worden, Matthew O. Old, Neal E. Dunlap, John M. Kaczmar, Yash Patil, Muhammed Kashif Riaz, Alice Tang, Jonathan Mark, Chad Zender, Ann M. Gillenwater, Diana Bell, Nicky Kurtzweil, Maria Mathews, Casey L. Allen, Michelle L. Mierzwa, Keith Casper, Roman Jandarov, Mario Medvedovic, J. Jack Lee, Nusrat Harun, Vinita Takiar, Maura Gillison
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (7): 1345–1352.
https://doi.org/10.1158/1078-0432.CCR-21-3351
Published: 01 April 2022
View article titled, Phase II Clinical Trial of Neoadjuvant and Adjuvant Pembrolizumab in Resectable Local–Regionally Advanced Head and Neck Squamous Cell Carcinoma
Open the PDF for Phase II Clinical Trial of Neoadjuvant and Adjuvant Pembrolizumab in Resectable Local–Regionally Advanced Head and Neck Squamous Cell Carcinoma in another window
Includes: Supplementary data